- 期刊
No Definite Benefit of 5-FU/LV Chemotherapy in Patient with Stage IIIColorectal Cancer but Only One Lymph Node Metastasis
5-FU/LV化學治療對於第三期大腸直腸癌只有一顆淋巴轉移病人並沒有明顯益處
摘要
目的 術後輔助性化學治療可以減低第三期大腸直腸癌病人的死亡率及復發率，我們分析第三期大腸直腸癌病人中只有一顆淋巴轉移的結果。方法 總共收案405個第三期大腸直腸癌只有一顆淋巴轉移的病人，於1990年2月27日至2006年9月18日在三軍總醫院及台北榮民總醫院接受手術，我們分析五年存活率及五年無疾病存活率。結果 回溯性觀察第三期大腸直腸癌只有一顆淋巴轉移的病人中有接受化療及沒有接受化療的數目分別為186和219位，比較兩組病人，較年輕的病人傾向接受化療(p = 0.04)，五年存活率在有接受化療及沒有接受化療的兩組中分別是65% 及68%，五年無疾病存活率分別是59.6%和57.2%，兩組都沒有達到統計學上意義(p = 0.576及p = 0.42)。結論 結果顯示5-FU/LV輔助性化學治療並沒有影響第三期大腸直腸癌只有一顆淋巴轉移的病人的五年存活率及三年復發率，因此化療對於這一個族群病人的影響還是值得討論。
關鍵字
第三期大腸直腸癌並列摘要
Purpose. Adjuvant chemotherapy can reduce mortality and recurrence of patients with stage III colorectal cancer (CRC). The purpose of this study is to evaluate efficacy of chemotherapy in patients with stage III colorectal cancer accompanied with solitary lymph node metastasis.Method. A total of 405 patients with stage III colorectal cancer and only one lymph node metastasis, who underwent surgery in Tri-Service General Hospital and Taipei Veterans General Hospital from February 27th, 1990, to September 18th, 2006, were enrolled. The patients with the number of total examined lymph nodes less than 12 were excluded. The 5-year overall survival rate and 5-year disease free survival rate were analyzed.Results. The number of patients with and without 5-FU/LV adjuvant chemotherapy was 186 and 219, respectively. Comparing the two groups, those younger patients tended to receive chemotherapy (p = 0.04). The 5-year overall survival rates in the stage III patients with only one lymph node metastasis, who received and didn’t receive adjuvant chemotherapy, were 65% and 68%, respectively. The 5-year disease free survival rates of the two groups were 59.6% and 57.2% respectively. Both results did not reach statistical significance. (p = 0.576 and p = 0.42)Conclusion. The result showed that 5-FU/LV adjuvant chemotherapy in stage III patients with solitary lymph node metastasis did not affect the 5-year overall survival and 5-year disease free survival. Therefore, applying 5-FU/LV chemotherapy for this group of patients with one lymph node metastasis is controversial.